Dec 29, 2025 • Stock Traders Daily
NEUTRAL
Trading the Move, Not the Narrative: (ALKS) Edition
This article provides an AI-driven analysis of Alkermes Plc (NASDAQ: ALKS), highlighting a neutral sentiment across all time horizons and suggesting a wait-and-see approach. It details distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, alongside multi-timeframe signal analysis suggesting sideways action for the stock. The article also mentions an exceptional risk-reward short setup for ALKS.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Alkermes plc $ALKS Shares Sold by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC reduced its stake in Alkermes plc (NASDAQ:ALKS) by 8.7% in the third quarter of 2025, selling 36,543 shares and retaining 385,342 shares valued at $11.56 million. Alkermes reported strong Q3 earnings, beating analyst expectations with an EPS of $0.49 and revenue of $394.19 million, and provided optimistic FY2025 guidance. Analysts maintain a "Moderate Buy" consensus rating for Alkermes with an average price target of $44.69.
Dec 27, 2025 • MarketBeat
NEUTRAL
Pacer Advisors Inc. Sells 98,825 Shares of Alkermes plc $ALKS
Pacer Advisors Inc. reduced its stake in Alkermes plc by 10.9% in the third quarter, selling 98,825 shares, though still holding 808,132 shares valued at $24.24 million. This comes after Alkermes surpassed Q3 earnings and revenue expectations, and despite insider selling activity, the company maintains a "Moderate Buy" consensus from analysts with an average target price of $44.69.
Dec 22, 2025 • Finviz
BULLISH
Why Analysts are Rating Alkermes (ALKS) a Buy
Analysts are largely bullish on Alkermes (ALKS), a promising mid-cap healthcare stock, with 11 out of 15 analysts assigning "Buy" ratings. The forecasted median 1-year price target suggests a 62.3% upside potential. The company's recent strategic moves, including the planned acquisition of Avadel and the development of new treatments for sleep disorders, are contributing to this positive outlook.
Dec 21, 2025 • Insider Monkey
BULLISH
15 Most Promising Mid-Cap Healthcare Stocks Under $50
This article highlights Alkermes plc (NASDAQ:ALKS) as one of the most promising mid-cap healthcare stocks under $50. Analysts maintain a bullish outlook on ALKS, with a consensus 1-year price target of $46.17, representing significant upside potential. The company's recent strategic moves, including an acquisition and plans for a new drug launch, further underscore its growth prospects within the neurological disorders and hypersomnolence markets.
Dec 21, 2025 • MarketBeat
BULLISH
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Alkermes plc (NASDAQ:ALKS) has received a "Moderate Buy" consensus recommendation from sixteen brokerages, with an average 12-month price target of $44.69. The stock recently reported strong Q3 earnings, exceeding analyst estimates, and has provided positive FY2025 EPS guidance. While institutional ownership is high at 95.21%, there have been insider stock sales totaling 25,748 shares in the last 90 days.